On Monday, Shares of Conagra Brands Inc (NYSE:CAG), added 1.60% and closed at $35.49 in the last trading session. The last trading range of the stock ranges between $34.81 and $35.79. Conagra Brands, Inc. (CAG) recently declared the appointment of Craig P. Omtvedt to its board of directors, effective right away. With this addition, the Conagra Brands board will consist of 10 members.
“We are very happy to welcome Craig to the Conagra Brands board,” said Steve Goldstone, chairman, Conagra Brands. “Craig’s strong financial and investment community expertise, and his deep experience in both the consumer packaged goods and retail industries, makes him a valuable asset to the company and our shareholders.”
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), jumped 6.76% and closed at $13.27 in the last trading session. The last trading range of the stock ranges between $12.42 and $13.38. The company’s Market capitalization is $2.72 Billion with the total Outstanding Shares of 194.20 million. In recognition of this month’s Lung Cancer Awareness Month, ARIAD Pharmaceuticals, Inc. (ARIA) recently declared the launch of an inaugural awareness day for anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) patients and their care partners. The awareness day is the first of its kind to specifically focus on ALK+ NSCLC and will be held on November 15th and subsequently on the third Tuesday of each November.
“This year we’re recognizing our 25 year anniversary as a company and we are extremely proud of our research efforts for rare cancers. This inaugural ALK+ Day, a collaborative engagement with the lung cancer patient advocacy community, has the aim to place progress made in the ALK+ NSCLC space within the context of advances made in non-small cell lung cancer research,” stated Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at ARIAD. “As we engage with the lung cancer community we aim to assist raise awareness about ALK+ NSCLC and encourage others to join the conversation about the R&D progress in this rare cancer space, in addition to the importance of mutation testing.”